3.710EUR+1.09%Mkt Cap: 123.09M EURP/E: —Last update: 2026-05-14
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activiti…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-12.12
PEG—
P/B22.87
P/S30.02
EV/EBITDA—
EV/Revenue—
EPS (TTM)-0.16
EPS (Forward)-0.30
Cash Flow & Leverage
FCF Yield—
FCF Margin—
Operating CF-2.93M EUR
CapEx (TTM)242.00K EUR
Net Debt/EBITDA—
Net Debt—
Technical
SMA 503.516 (+5.5%)
SMA 2003.534 (+5.0%)
Beta0.58
S&P 52W Chg24.23%
Avg Vol (30d)96.98K
Avg Vol (10d)73.12K
Technical Indicators
RSI (14)58.0
MACD0.0221
MACD Signal0.0128
MACD Hist.+0.0093
BB Upper3.878 EUR
BB Middle3.618 EUR
BB Lower3.358 EUR
BB Width14.37%
ATR (14)0.1694 EUR
Vol Ratio (20d)1.01x
52W Range
1.17062% of range5.290
52W High5.290 EUR
52W Low1.170 EUR
Profitability
Gross Margin13.14%
EBITDA Margin-131.10%
Profit Margin-136.60%
Oper. Margin-160.02%
ROE-123.01%
ROA-42.32%
Revenue Growth-10.20%
Earnings Growth—
Balance Sheet
Debt/Equity0.84
Current Ratio—
Quick Ratio—
Book Value/Sh0.1570 EUR
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.34.29M
Float—
Insiders35.55%
Institutions4.48%
Analyst Consensus
Rating—
Target (Mean)10.50 EUR
Target Range10.00 EUR – 11.00 EUR
# Analysts2
Company
Market Cap123.09M EUR
Enterprise Value—
Revenue (TTM)4.10M EUR
Gross Profit534.00K EUR
Net Income (TTM)-5.55M EUR
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price3.710 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012616852